Diagnosis et Treatment of Asthma in Athlete : Boundary Between Disease and Doping

This study will determine the pharmacokinetic profile of the salbutamol concentration in the urine while athletes are resting or during exercise.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

UH Toulouse

Toulouse, 31, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patient who hold a license in a sport federation, and do at least 8 hours of sport each week
asthmatic patient

Exclusion criteria

Treatment and study plan

blood sample

Other

blood sample

Urine sample

Other

urine sample

Primary outcomes

impact of exercise on pharmacokinetics profile

Time frame: 4 days

impact of exercise on pharmacokinetics profile of salbutamol concentration in urine

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Acronym: SALBEXO

Important dates

Study start: 2009
Primary completion: 2013
Study completion: 2013
First posted: Jan 14, 2016
Registry last updated: Jan 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed